Reserpine

  • TRADE NAMES: Anserpin; Inerpin; Novo-Reserpine; Resa; Reserfia; Sedaraupin; Ser-Ap-Es (Novartis); Serpalan; Serpasil (Novartis); Serpasol; Serpatabs; Tionsera
  • INDICATIONS: Hypertension
  • CLASS: Rauwolfia alkaloid
  • HALF-LIFE: 50–100 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atenolol, Bisoprolol, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Iobenguane, Linezolid, Metipranolol, Oxprenolol, Sotalol, St John's Wort, Tetrabenazine

PREGNANCY CATEGORY: C

Ser-Ap-Es is reserpine, hydralazine and hydrochlorothiazide.

Our database has 9 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM


Page last updated 03/02/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric